A. Kaushal

Panjab University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Kevin Camphausen

Foundation for the National Institutes of Health

Judith A. Clements

Translational Research Institute

Deborah E. Citrin

National Cancer Institute

Elena Lita

University of Nevada, Las Vegas

Andra Krauze

National Cancer Institute

Ying Dong

Beijing Hospital

Deborah McNally

National Cancer Institute

Peter L. Choyke

National Cancer Institute

H. Ning

Hunan Agricultural University

Hemamali Samaratunga

University of Queensland

Cooperative Institutions

National Institutes of Health

National Cancer Institute

Center for Cancer Research

Cancer Institute (WIA)

21st Century Oncology (United States)

University of Queensland

Molecular Oncology (United States)

National Institutes of Health Clinical Center

National Cancer Institute

Queensland University of Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Assessment of Multiparametric Magnetic Resonance Imaging for the Detection of Local Recurrence After Low-Dose-Rate Brachytherapy

International Journal of Radiation Oncology*Biology*Physics (2016)

L. Valle Matthew D. Greer Akhil Muthigi Andra Krauze A. Kaushal

Prostate brachytherapy

Multiparametric MRI

10.1016/j.ijrobp.2016.06.1240

Cite

Citations (0)

Urinary c-Met, a Novel Biomarker of Metastatic Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics (2008)

M. Wernick Alessia Russo K Jedlicka Deborah McNally Uma Shankavaram

10.1016/j.ijrobp.2008.06.895

Cite

Citations (0)

A novel transcript from the KLKP1 gene is androgen regulated, down‐regulated during prostate cancer progression and encodes the first non‐serine protease identified from the human kallikrein gene locus

The Prostate (2008)

A. Kaushal Stephen Myers Ying Dong John Lai Olivia L. Tan

Abstract BACKGROUND The kallikrein‐related (KLK) serine protease, prostate specific antigen is the current marker for prostate cancer (PCa). Other members of the KLK family are also emerging as potential adjunct biomarkers for this disease. Our aim was to identify and characterize novel KLK ‐related genes with potential as PCa bio‐markers. METHODS Low stringency DNA screening was coupled with amplification techniques to identify novel sequences. Transcripts were examined by Northern blot, RT‐PCR, and in situ hybridization analysis and in silico bioinformatics approaches. Protein characterization was performed by Western blot and confocal microscopy analysis. Gene regulation studies were performed by quantitative PCR and promoter reporter assays. RESULTS We identified a novel kallikrein‐related mRNA designated KRIP1 ( k allikrein‐ r elated, expressed i n p rostate 1 ) which, together with the recently reported ΨKLK1 and KLK31P transcripts, is transcribed from KLKP1 ; a gene evolved from, and located within, the KLK locus. Significantly, in contrast to these other non‐coding KLKP1 transcripts, the KRIP1 mRNA generates an ∼18 kDa intracellular protein—the first non‐serine protease identified from the KLK locus. KRIP1 mRNA is abundant only in normal prostate and is restricted to cells of epithelial origin in normal and diseased glands. Ligand binding of the androgen receptor increases transcription from the KLKP1 gene. Consistently, KRIP1 mRNA levels are lower in PCa samples compared to benign prostatic hyperplasia. CONCLUSIONS Transcription from KLKP1 is reduced as cells de‐differentiate on the pathway to malignancy. KLKP1 /KRIP1 has potential as a marker of both PCa progression and recent evolutionary events within the KLK locus. Prostate 68: 381–399, 2008. © 2008 Wiley‐Liss, Inc.

Northern blot

10.1002/pros.20685

Cite

Citations (22)

A Novel Approach to Diffusion Weighted Imaging Analysis in Newly Diagnosed GBM

International Journal of Radiation Oncology*Biology*Physics (2015)

Ying Zhuge He Ning J.Y. Cheng Robert S. Kirkland B. Arora

Concordance

Grading (engineering)

Brain tumor

Imaging biomarker

Concordance correlation coefficient

10.1016/j.ijrobp.2015.07.775

Cite

Citations (1)

Optimizing Emotion Recognition in EEG Data: A Genetic Algorithm Approach with XAI Insights

2022 13th International Conference on Computing Communication and Networking Technologies (ICCCNT) (2024)

Noman Ali Mohammad Asif A. Kaushal Upinderpal Singh Uma Shanker Tiwary

10.1109/icccnt61001.2024.10725514

Cite

Citations (0)

Urinary-activated HGF as a noninvasive biomarker for the diagnosis of prostate cancer.

Journal of Clinical Oncology (2011)

Chuan Peng Alisa J. Prager Elena Lita M. Wernick Deborah McNally

e15144 Background: Hepatocyte growth factor or scatter factor has been linked to the proliferation, motility, and metastatic invasion of cancer cells. Pro-HGF, an inactive precursor, is cleaved into a biologically active heterodimeric form called activated HGF (AHGF). We evaluated the potential of AHGF as a diagnostic and prognostic urinary biomarker candidate for prostate cancer. Methods: Urinary levels of AHGF were determined via enzyme linked immunosorbent assay (Immuno-Biological Laboratories Co., Ltd, Japan) in duplicate. Samples were compared between men with localized (n=65) and metastatic (n=36) cancer and a healthy control group of men (n=19). AHGF concentrations were normalized with creatinine (Bayer DCA 2000+ Analyzer). Results: The difference of urinary AHGF levels between the control group (mean: 111.3 pg/mg, range: 27.0-250.0) and the prostate cancer groups (mean: 230.1 pg/mg, range: 20.9-1010.0) was statistically significant (p<0.0001). Furthermore, urinary AHGF concentrations were significantly different between the control and the localized group (mean: 235.2 pg/mg, range: 24.6-668.0) (p<0.0001) and between the control and the metastatic group (mean: 220.8 pg/mg, range: 20.9-1010.0) (p=0.0039). The area under the receiver operating characteristic curve associated with the diagnostic accuracy of HGF between control and prostate cancer groups was 0.75 (p=0.0006, 0.64 to 0.85 confidence interval). There was no significant difference between the localized and metastatic groups. Conclusions: Urinary levels of activated HGF have the potential as a novel noninvasive diagnostic marker for prostate cancer.

10.1200/jco.2011.29.15_suppl.e15144

Cite

Citations (0)

A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus

Faculty of Science and Technology; Institute of Health and Biomedical Innovation (2008)

A. Kaushal Stephen Myers Ying Dong John Lai Olivia L. Tan

BACKGROUND: The kallikrein-related (KLK) serine protease, prostate specific antigen is the current marker for prostate cancer (PCa). Other members of the KLK family are also emerging as potential adjunct biomarkers for this disease. Our aim was to identify and characterize novel KLK-related genes with potential as PCa bio-markers. METHODS: Low stringency DNA screening was coupled with amplification techniques to identify novel sequences. Transcripts were examined by Northern blot, RT-PCR, and in situ hybridization analysis and in silico bioinformatics approaches. Protein characterization was performed by Western blot and confocal microscopy analysis. Gene regulation studies were performed by quantitative PCR and promoter reporter assays. RESULTS: We identified a novel kallikrein-related mRNA designated KRIP1 (kallikrein-related, expressed in prostate 1) which, together with the recently reported PsiKLK1 and KLK31P transcripts, is transcribed from KLKP1; a gene evolved from, and located within, the KLK locus. Significantly, in contrast to these other non-coding KLKP1 transcripts, the KRIP1 mRNA generates an approximately 18 kDa intracellular protein-the first non-serine protease identified from the KLK locus. KRIP1 mRNA is abundant only in normal prostate and is restricted to cells of epithelial origin in normal and diseased glands. Ligand binding of the androgen receptor increases transcription from the KLKP1 gene. Consistently, KRIP1 mRNA levels are lower in PCa samples compared to benign prostatic hyperplasia. CONCLUSIONS: Transcription from KLKP1 is reduced as cells de-differentiate on the pathway to malignancy. KLKP1/KRIP1 has potential as a marker of both PCa progression and recent evolutionary events within the KLK locus.

Northern blot

Source

Cite

Citations (4)

Tumor Nodule Location Predicts the Feasibility of Intraprostatic High-dose Irradiation in Men with Localized Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics (2009)

Nadine Housri John Ondos Peter L. Choyke A Barbara H. Ning

Nodule (geology)

10.1016/j.ijrobp.2009.07.340

Cite

Citations (1)

WITHDRAWN